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PURPOSE. To provide the first detailed clinical description in patients with RP caused by
recessive mutations in IMPG2.
METHODS. This international collaborative study includes 17 RP patients with inherited retinal
disease caused by mutations in IMPG2. The patients were clinically (re-)examined, including
extensive medical history taking, slit-lamp biomicroscopy, ophthalmoscopy, perimetry, ERG,
optical coherence tomography (OCT), fundus autofluorescence (FAF) imaging, fundus
photography, and color vision tests. The main outcome measures included mean age at onset,
initial symptom, best-corrected visual acuity, fundus appearance, perimetry results, ERG
responses, OCT images, FAF imaging, color vision test reports and DNA sequence variants.
RESULTS. The mean age at onset was 10.5 years (range, 4–20 years). Initial symptoms included
night blindness in 59% of patients, a decreased visual acuity in 35%, and visual field loss in 6%.
Fundus abnormalities were typical of RP: optic disc pallor, attenuated vessels, bone spicules,
and generalized atrophy of the retina and choriocapillaris. Additionally, we observed macular
abnormalities in all patients, ranging from subtle mottling of the macular pigment epithelium
(two patients) and a bull’s eye maculopathy (seven patients) to macular chorioretinal atrophy
(seven patients).
CONCLUSIONS. Mutations in IMPG2 cause a severe form of RP with symptoms manifesting in the
first 2 decades of life. IMPG2-associated RP is frequently accompanied by macular
involvement, ranging from mild pigment alterations to profound chorioretinal atrophy. The
resulting decrease in central vision in combination with the severe tunnel vision leads to
severe visual impairment in patients with IMPG2-associated RP.
Keywords: Retinitis pigmentosa, IMPG2, macular atrophy, bull’s eye maculopathy, natural
course.
Retinitis pigmentosa (RP) is a group of diseases featuringprogressive degeneration of rod and cone photoreceptor
cells and RPE, and is considered the most commonly inherited
retinal dystrophy with an estimated prevalence of approxi-
mately 1:4000.1–3 Retinitis pigmentosa typically starts with
night blindness followed by loss of the peripheral visual field
that leads to tunnel vision, whereas visual acuity often remains
normal until the late stages.3,4 Hallmark fundus abnormalities in
RP are bone-spicule pigmentation, a waxy pale optic disc, and
attenuation of retinal vessels. Electroretinography (ERG)
responses reveal rod and cone dysfunction, where rod
abnormalities often are observed earlier in the course of the
disease. However, wide variability in terms of disease onset,
progression rate, and degeneration patterns are observed in
RP.4,5
The genetic background underlying RP is also very
heterogeneous. Inheritance modes observed in RP include
autosomal-recessive (30% of patients), autosomal-dominant
(20%), X-linked (10%), mitochondrial (<1%) patterns, and a
few cases of digenic RP.6–9 However, the remaining 40% of
patients are isolated cases.10 Autosomal recessive RP is
currently associated with mutations in 42 different genes
(RetNet, available in the public domain at https://sph.uth.edu/
retnet/), which provide a molecular genetic explanation for
approximately 50% of all recessive RP cases.11 The proteins
encoded by these genes are involved in a broad range of cellular
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functions, including phototransduction, the visual (retinoid)
cycle, transport along the connecting cilium, cell-to-cell
signaling or synaptic interaction, gene regulation, cell or
cytoskeletal structure, cell-cell interactions, and outer segment
phagocytosis.4,10,12
Recently, mutations in the IMPG2 gene have been
implicated in autosomal recessive RP.13 This gene encodes
the interphotoreceptor matrix proteoglycan-2 (IMPG2),
formerly known as IPM 200 or SPACRCAN,14 which is
localized in the retinal extracellular matrix (also known as
the interphotoreceptor matrix [IPM]). The IPM is a viscous
substance mainly composed of glycoproteins and proteogly-
cans that fills the space between individual photoreceptor
cells and between photoreceptors and the RPE.15,16 For many
years, the IPM was considered merely a fixating medium,17
but in the past few decades multiple functions of the IPM
have been reported, including important functions in
intercellular communication, regulation of neovasculariza-
tion, cell survival, membrane turnover, photoreceptor
differentiation and maintenance, retinoid transport, matrix
turnover, and the precise alignment of the photoreceptor
cells to the optical light path.14,18,19 Both rod and cone
photoreceptor cells synthesize IMPG2 and secrete the
protein into the IPM,20 where it binds to other proteins,
such as hyaluronan, and also seems to be anchored in the
plasma membrane of the photoreceptor cells, thereby
fixating the photoreceptors in the IPM.21 Additionally, IMPG2
is thought to have calcium-binding potential, which suggests
it has an important role in sequestering extracellular calcium
released by photoreceptors in response to light.21
Knowledge of the natural course of IMPG2-related RP is of
significant importance for prognosis counseling as well as
genetic counseling. Furthermore, this knowledge is vital in the
view of emerging therapy trials, in terms of patient selection
and the assessment of treatment effects. In this international
collaborative study, we aim to provide a detailed overview of
the clinical findings in patients with IMPG2-associated RP.
METHODS AND PATIENTS
Subjects and Genetic Analysis
The specialized ophthalmogenetic centers of the Radboud
University Medical Center (RACvH, CBH, and BJK), the
Rotterdam Eye Hospital (LIvdB), the Erasmus University
Medical Center Rotterdam (CCWK), the Hadassah-Hebrew
University Medical Center in Jerusalem (EB), the Seconda
Universita` degli Studi di Napoli (FS), and the Shifa College of
Medicine in Islamabad (RQ) participated in this study. As
described previously,13 six families of Israeli, Palestinian,
Pakistani, Italian, or Dutch origin were found to carry
causative mutations in IMPG2 (families A–F, Fig. 1). Addition-
ally, we selected four more families after identification of
causative IMPG2 mutations in a targeted next-generation
sequencing experiment in 100 Dutch RP probands (family
G),22 or whole exome sequencing (families H, J, K, Fig. 1).
Exome sequencing was performed using the 5500xl Genetic
Analyzer of Life Technologies (Applied Biosystems, Foster
City, CA, USA) and the Agilent SureSelectXT Human All Exon
50-Mb amplification kit (Agilent Technologies, Inc., Santa
Clara, CA, USA). Data were analyzed with LifeScope software
(version 2.1; Life Technologies, Applied Biosystems). All
mutations were confirmed with Sanger sequencing.
We adhered to the tenets of the Declaration of Helsinki and
obtained approval for this study from the Institutional Ethics
Committee from the Radboud University Medical Center.
Approval included permission to use the documented medical
data and, when indicated, clinically reassess affected individ-
uals and to obtain blood for the purposes of DNA extraction
and genetic analysis. We obtained informed consent from all
participants before the collection of blood samples and
additional ophthalmologic examinations.
Clinical Analysis
We collected the available clinical data from the medical files of
all patients. Nine patients were clinically reevaluated after the
identification of causative IMPG2 mutations. Medical history
was registered with a focus on the age at onset, initial
symptoms, and the overall course of the retinal disorder. The
age at onset was defined as the age at which the initial
symptom was noticed by the patient. Additionally, we
questioned patients about the presence of syndromic features,
which generally occur in 20% to 30% of RP patients.4 This
questionnaire included the presence of hearing and balance
abnormalities, renal failure, cardiac and respiratory anomalies,
polydactyly, obesity, cognitive impairment, fertility disorders,
hypogonadism, and dental anomalies.
Clinical examination included best-corrected visual acuity
(BCVA), slit-lamp biomicroscopy, and ophthalmoscopy. Addi-
tional examinations were performed if feasible. Goldmann
(kinetic) perimetry was performed in 11 patients using targets
V-4e, III-4e, I-4e, I-3e, I-2e, and I-1e. In two patients (F-II:1 and
F-II:2) perimetry was restricted to analysis of the central 308
of the visual field with the Humphrey perimeter (Carl Zeiss
Meditec, Jena, Germany). In all but one patient (F-II:2), full-
field ERG was performed according the guidelines of the
International Society for Clinical Electrophysiology of Vi-
sion.23 Results were compared to the local reference values.
We evaluated color vision in six patients using the Farnsworth
Dichotomous Test (Panel D-15) and/or the Hardy-Rand-
Rittlers test. Fundus photographs of the central retina
(Topcon TRC50IX; Topcon Corporation, Tokyo, Japan) were
obtained in 15 patients. Fundus autofluorescence images
(Spectralis; Heidelberg Engineering, Heidelberg, Germany) of
the central retina were acquired in eight patients using a
confocal scanning laser ophthalmoscope with an optically
pumped solid state laser (488 nm) for excitation. Spectral-
domain optical coherence tomography (SD-OCT, Spectralis;
Heidelberg Engineering) could be performed in 13 patients.
In three patients, a high-resolution OCT was not available and
a time-domain OCT (Stratus; Carl Zeiss Meditec) was
obtained. No OCT images were available for the remaining
four patients. In eight Dutch patients with high-resolution SD-
OCT images (mean age: 51 years; range, 23–67 years), we
quantified thickness of the total retina at the foveola and at
0.25, 0.5, 1.0, 1.5, 2.0, and 2.5 mm eccentricity from the
foveola in the right eye using the thickness graphs in the
Heidelberg Eye Explorer Software (version 1.6.4.0; Heidel-
berg Engineering). In seven of these patients, we quantified
the foveal volume by measuring the retinal volume within the
central 3 mm2 using the thickness map in the Heidelberg Eye
Explorer Software (version 1.6.4.0; Heidelberg Engineering).
A normal dataset of retinal thickness and foveal volume in
individuals without (vitreo)retinal disease was obtained from
25 age-matched Dutch individuals (mean age: 46 years; range,
27–62 years) for reference purposes.
RESULTS
Ten families with a total of 17 affected individuals were
included in this study. The pedigrees of all families are depicted
in Figure 1. An overview of the clinical findings in all 17
patients is provided in Table 1.
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Clinical Evaluation
The most recent examination of the 17 RP patients was
performed at a mean age of 49 years (range, 23–67 years). The
mean age at onset was 10.5 years (range, 4–20 years), and night
blindness was the most frequent initial symptom, occurring in
10 patients (59%). Other initial symptoms were decrease in
visual acuity (35%) and loss of visual field (6%). In the patients
who initially revealed a decreased visual acuity, normal BCVA
was measured before the decrease in visual acuity, which
excludes refractive amblyopia. In one patient (A-II:6), the
diagnosis of RP was made during a routine ophthalmologic
consultation when he was 12 years old. At that time, he had
not noticed any symptoms associated with RP, but later in the
course of the dystrophy, night blindness manifested as the first
FIGURE 1. Pedigrees of the families that were included in this study. Where relatives were available (families A, B, C, F, G, and H), the mutation
segregates with the disease. Plus signs denote the wild-type allele, square boxes indicate men, circles indicate women, and affected individuals are
pointed out in black. The arrows indicate the probands. Double lines point out consanguineous marriages, the numbers indicate the degree of
consanguinity. The dagger (†) indicates the patients diagnosed with RP not included in this study due the lack of clinical data.
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symptom at age 24. In eight patients, an extended clinical
follow-up period varying from 14 to 48 years was available
(mean: 29 years). The course of the BCVA for each of these
patients during follow-up is represented in Figure 2. None of
the patients showed extraocular abnormalities that are
indicative of syndromic RP.
Refractive errors included mild to high myopia (range of
spherical equivalents: plan to 12.00 diopters; Table 1).
Significant lens opacities were observed in 13 patients, most
often subcapsular posterior cataracts (seven patients [41%],
Table 1). Six patients had experienced cataract surgery, most
often in the fourth decade (five of six patients). Ophthalmos-
copy revealed the classic RP features, including bone spicule
pigmentation at the (mid)periphery, attenuated vessels, waxy
pallor of the optic disc, and atrophy of the RPE and
choriocapillaris in all RP patients. In one patient (A-II:5),
marked sheathing of the peripheral retinal vessels was noted
(Fig. 3A). In addition, all patients revealed macular abnormal-
FIGURE 2. Graph showing the change in visual acuity (y-axis) related to the age in years (x-axis) in patients carrying mutations in the IMPG2 gene.
Snellen visual acuity was transformed into logMAR for visualization purposes. A logMAR value of 1.9 was assigned to counting fingers (CF), 2.3 to
hand movements (HM), and 2.7 to light perception (LP). When the visual acuity differed in both eyes, the visual acuity of the best eye was used. The
improvement in visual acuity in patient A-II:5 was seen after cataract surgery; subsequently, the decrease in visual acuity was probably due to cystoid
macular edema, which was successfully treated. The cause of the improvement in patient J-II:1 is unclear, because refractive, optical, or retinal
causes seemed absent.
FIGURE 3. Fundus photographs and FAF imaging of patients carrying mutations in IMPG2. (A and F) Fundus photograph of temporal superior
region of the retina (A), showing sheathing of the retinal vessels, and FAF imaging of the central retina (G), revealing irregular FAF signal in the
macula and a granular hypoautofluorescent aspect of the RPE surrounding the posterior pole, in patient A-II:5 (age 45). (B and H) Fundus
photograph composition (G), showing macular atrophy, and FAF images (I), revealing a hypoautofluorescent macula, a granular aspect with large
confluent hypoautofluorescent lesions in the midperiphery, and peripapillary hypoautofluorescence, of patient G-II:1 (age 60). (C and E) Fundus
photograph (C) and FAF image (F) of the central retina in patient A-II:6 (age 44). The fundus photograph reveals a BEM. The FAF image shows
granular aspect of the macula, whereas deeper perifoveal hypoautofluorescence gives the impression of a BEM, mottled aspect of midperiphery
with larger hypoautofluorescent lesions. (D and G) Fundus photograph (D) and FAF image (H) of the central retina in patient K-II:1 (age 67). The
fundus photograph shows a BEM, whereas FAF reveals a mottled hypoautofluorescent aspect of the perifoveal region, hyperautofluorescence in the
fovea, and a mottled aspect just anterior of the vascular arcades.
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ities ranging from subtle changes, such as mottling of the
macular RPE as observed in C-II:2 and J-II:1, to profound
macular atrophy as was observed in seven patients (mean age:
57 years; range, 36–66, Fig. 3B). A bull’s eye maculopathy
(BEM) was a distinctive ophthalmoscopic feature in six
patients, which mainly was observed during the fifth and sixth
decades of life (mean age: 51 years; range, 32–67 years, Figs.
3C, 3D, 4A). Since the exact onset of the BEM could not be
ascertained, we were unable to define the interval in which the
BEM had been present in these patients. Progression of a BEM
to atrophy covering the whole fovea was observed in the
follow-up data of patient G-II:1.
Perimetry revealed visual field constriction resulting in
tunnel vision of 208 or less in nine patients (mean age: 48 years;
range, 23–66 years; Fig. 5). Macular involvement was apparent
by a gradual decrease in central sensitivity, which we observed
in 10 patients (mean age: 40 years; range, 23–66 years). We
observed paracentral scotomas in two patients (C-II:2 and C-
II:3) with a relatively intact (mid)peripheral visual field (Fig.
5C). Additionally, paracentral scotomas were present in
patients F-II:1 and F-II:2, in whom only the central 308 was
analyzed with the more sensitive static perimeter (Table 1).
Electroretinographic responses were nonrecordable in 11
patients (mean age: 51 years). In five patients (mean age: 31
years), a severely reduced photoreceptor dysfunction was seen
in a rod-cone pattern. Evaluation of color vision resulted in an
isolated tritan defect in patients A-II:6, G-II:1, and G-II:2 at ages
24, 40, and 39, respectively, whereas patients C-II:2 and C-II:3
demonstrated strong protan, deutan, and tritan defects at ages
33 and 36, respectively. In patient A-II:5, we did not detect
color vision defects.
Fundus autofluorescence (FAF) images revealed macular
involvement in all eight patients for whom FAF imaging was
available. The macular aspects varied from hyperautofluores-
cence to profound hypoautofluorescent RPE lesions (mean
age: 51 years; range, 23–67 years, Figs. 3E–G, 3I, 4B).
Midperipheral changes include granular or mottled hypoauto-
fluorescent changes that are spread to the vascular arcades. In
some patients, large (confluent) hypoautofluorescent lesions
were observed just anterior of the vascular arcades (Figs. 3E,
3H). Evaluation of the central retinal structure with SD-OCT
revealed loss of photoreceptors before RPE cell loss, which
eventually result in moderate to severe retinal thinning (Fig.
6A). The foveal volume in seven Dutch RP patients (mean age:
49 years; range, 23–67) was significantly lower compared with
the foveal volume in 25 age-matched Dutch healthy controls (P
< 0.0001; Fig. 6B). In all patients with high-resolution SD-OCT,
except in G-II:2, the bands corresponding to the photoreceptor
inner and outer segments were lost.24 The outer nuclear layer,
containing the photoreceptor cell bodies, was concentrically
lost and severely thinned where present. We observed
concentric atrophy of the layer that corresponds to the RPE
cells that progressed from the midperiphery. The central
abnormalities in the RPE layer started in the parafoveal region,
FIGURE 4. Multimodal imaging of the central retina in patient G-II:2 at the age of 59. (A) Fundus photograph showing a BEM, attenuated vessels,
peripapillary atrophy, pale optic disc, bone-spicule pigmentations, and chorioretinal atrophy in the midperiphery. (B) Autofluorescence imaging
shows a subtle hyperautofluorescent ring around the macula, spots of decreased macular and peripheral autofluorescence, and absence of
autofluorescence corresponding with the peripapillary atrophy. (C) Spectral domain OCT reveals loss of the bands corresponding to the
photoreceptor inner and outer segments in the macula. The external limiting membrane is present only in the fovea. The RPE layer seems fairly
intact, except for irregular thinning in the fovea and loss of RPE in the peripapillary region. (D) Infrared en face image reveals the location of the SD-
OCT image (green line).
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as was observed in four patients who also revealed a BEM (Fig.
6D). In patient J-II:1, who displayed mottling in the macula, the
RPE appeared normal on SD-OCT (Fig. 6E). In later stages of
the disease, we observed loss of the foveal RPE layer, which
was highlighted by a increased beam penetration and choroidal
reflection in patients E-II:4 and G-II:1 (Fig. 6F). Spectral-domain
OCT scans in the midperiphery revealed loss of the photore-
ceptor-RPE complex and intraretinal pigment deposits in
patients G-II:1 and G-II:2 at ages 60 and 59, respectively (Fig.
6G), whereas patient J-II:1 at the age of 23 revealed only
photoreceptor loss (Fig. 6H).
Mutation Analysis
A description of the molecular genetic findings in families A to
F were reported earlier.13 In summary, sequence analysis of all
19 coding exons of IMPG2 led to the identification of 10
different pathogenic variants in these 17 patients (Table 2). In
the families with available family members, the homozygous or
compound heterozygous mutations segregated completely
with the RP phenotype (Fig. 1).13
In addition to the mutations described earlier,13 four new
pathogenic variants in IMPG2 were identified. In family G, a
targeted next-generation sequencing approach that covered
111 blindness genes resulted in two compound heterozygous
mutations: a nonsense mutation (p.Arg127*), which is predict-
ed to cause premature truncation of the IMPG2 protein, and a
4-base-pair deletion (c.3423-8_c.3423-5del) that affects the
splice acceptor site (Table 2).22 Reverse transcriptase PCR
analysis on RNA isolated from patients’ lymphoblastoid cells
revealed that, instead of the regular splice acceptor site, a
second splice site located upstream in the same intron is used
that results in the inclusion of 80 additional nucleotides to
IMPG2 mRNA, subsequently leading to a frameshift and
premature termination of IMPG2 (Supplementary Fig. S1).
The cDNA products generated from RNAs isolated from cells
grown under nonsense-mediated decay (NMD)-suppressing
conditions show subtle differences compared with those
generated from RNAs isolated from cells grown under normal
conditions. Growing cells under NMD-suppressing conditions
did not yield an obvious difference in the amount of aberrantly
spliced IMPG2, indicating that a truncated protein may be
produced. The other novel mutations include a nonsense
mutation (p.Tyr171*) and a missense mutation (p.Ser379Pro).
The nonsense mutation is predicted to cause a premature
truncation of IMPG2. The p.Ser379Pro missense mutation
changes a highly conserved amino acid and is unanimously
predicted to be pathogenic by multiple in silico prediction
tools (SIFT: deleterious [score: 0], Polyphen-2: probably
damaging [score: 1.000], Align GVGD: Class C65, MutationTast-
er: disease causing [probability: 0.994], Grantham score: 74,
PROVEAN prediction: deleterious [score: 2.972]).
DISCUSSION
The Phenotype of IMPG2-Associated RP
In this study, we provide a detailed clinical description of the
RP associated with mutations in IMPG2, a gene that recently
was added to the long list of genes that may cause autosomal
recessive RP when mutated.13 Most of the patients with
IMPG2-associated RP demonstrated the classic RP symptoms:
night blindness and progressive concentric loss of the visual
field. However, 6 of 17 patients mentioned a decrease in BCVA
that could not be attributed to amblyopia as the initial
symptom. Loss of vision as the initial symptom is not just a
result of our electrically illuminated nighttime environment
that compensates for an impaired night vision,4,5 but a
consequence of macular abnormalities that are a prominent
feature of this type of RP. Overall, the BCVA progressively
decreased during the first 4 decades of life, and subsequently
deteriorates to levels lower than 20/300 during the fifth and
sixth decades of life. The only exception was patient G-II:2,
who still enjoyed a BCVA of 20/30 at the age of 59.
Thirteen of the 17 RP patients included in this study
showed significant macular abnormalities: a BEM was observed
in six patients (mean age: 51 years) and profound macular
atrophy in seven patients (mean age: 57 years). We hypothesize
that the perifoveal atrophy, manifesting as a bull’s eye pattern,
FIGURE 5. Goldmann perimetry findings in the right eyes of patients J-II:1 (age 23, A), H-II:2 (age 35, B) C-II:3 (age 37, C), and G-II:2 (age 59, D). The
colored lines indicate the outer borders of the isopters. The filled areas indicate scotomas for the isopter of that color.
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eventually progresses to macular atrophy with profound
degeneration of photoreceptors and RPE, although this was
observed only in patient G-II:1 because longitudinal data of the
other patients with macular atrophy were not available. The 13
patients with macular involvement displayed a decreased
central sensitivity and/or paracentral scotomas on visual field
examination in addition to the concentric constriction that is
typically seen in RP (Table 1; Fig. 5). Spectral-domain OCT of
the macula showed early loss of photoreceptor inner and outer
segments before loss of the RPE layer in the central retina. On
FAF imaging, macular hypoautofluorescence was observed,
whereas hypoautofluorescence in the midperiphery generally
had a granular aspect. In contrast to the significant macular
involvement that was observed in most patients, subtle
macular FAF abnormalities appeared in patients C-II:2 and J-
II:1. However, subtle macular FAF abnormalities have been
observed in other forms of RP with intact central vision and
therefore do not automatically predate loss of macular
function.25
A BEM is a nonspecific reaction of the posterior pole, which
can occur in various diseases affecting the bipolar cell layer,
photoreceptor cell layer, or RPE.26 It is not often observed in
RP, but has been reported in some specific forms of syndromic
and nonsyndromic RP,27–31 and is associated with a faster
deterioration of the visual acuity compared with RP without
specific macular lesions.32 Concerning the BEM in IMPG2-
associated RP, multimodal imaging revealed abnormalities in
the photoreceptor and RPE cell layers. However, it is unclear
why RPE abnormalities initially predominate in the perifoveal
region, as the preceding abnormalities in the photoreceptor
layer are ubiquitously present. Possible explanations may
include topographical differences in metabolism and cell
densities,33 the higher vulnerability of S (‘‘blue’’) cone
photoreceptors to retinal disease compared with M and L
cones,34 and the higher vulnerability of parafoveal rods to
aging and light-induced damage.35–37 In patient G-II:2 (age 59),
we observed a prominent BEM due to hypopigmentation
rather than atrophy of the perifoveal RPE, as there were only
minor RPE changes on FAF imaging (Fig. 4B) and mild changes
of the band corresponding to the photoreceptor outer
segment–RPE complex (Fig. 4C). By contrast, other patients
with BEM revealed perifoveal hypoautofluorescence indicating
FIGURE 6. Optical coherence tomography examinations in patients with IMPG2-associated RP. (A) Thickness of the total retina in eight Dutch
patients (mean age: 49 years; range, 23–67). Shaded areas: normal limits (mean 6 2 SDs) as measured in 25 controls (mean age: 46 years). (B)
Foveal volume (mm3) measured in the central 3 mm2 in these patients except patient A-II:1. The foveal volume in seven Dutch IMPG2-associated RP
patients (mean age: 49 years; range, 23–67) was significantly lower than in 25 age-matched healthy Dutch controls (P < 0.0001). The horizontal bars
indicate the median of the corresponding cohort. (C) Spectral-domain OCT scan of a normal central retina (age 25). The hyperreflective bands
correspond to the external limiting membrane (1), the ellipsoid photoreceptor inner segments (2), the photoreceptor outer segment/RPE contact
cylinder region (3), and the RPE (4).24 (D) Spectral-domain OCT of patient A-II:6 (age 44) that reveals generalized loss of the outer retinal layers,
whereas the RPE reflectance is fairly intact expect for the irregular signal and thinning in the temporal parafovea (white arrowhead). (E/H)
Spectral-domain OCT in patient J-II:1 (age 23). The central retina (E) revealed normal bands corresponding to the RPE, whereas the photoreceptor
bands are absent outside the fovea. The midperipheral retina (H) reveals loss of the photoreceptor inner and outer segment bands. However, no
profound RPE atrophy or intraretinal pigment deposits were observed yet. (F and G) Spectral-domain OCT of patient G-II:1 (age 60). The central
retina (F) reveals generalized loss of photoreceptor inner and outer segments, a thinned outer nuclear layer, and patchy loss/thinning of the foveal
RPE. The midperipheral retina (G) shows profound loss of the outer retinal layers, RPE and choriocapillaris reflectance, as well as intraretinal
pigment deposits.
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perifoveal RPE atrophy (Figs. 3E, 3G). In late stages of the
disease, profound macular hypoautofluorescence developed,
which is indicative of RPE atrophy (Fig. 3H). In the light of
future therapeutic options for retinal dystrophies, knowledge
of the natural course of IMPG2-associated retinal disease is
necessary to select patients amenable for treatment and to
correctly interpret the effect of therapeutic intervention.
Genotype-Phenotype Correlation
Bandah-Rozenfeld et al.13 identified mutations only with severe
effects on the IMPG2 protein in RP patients, whereas a
homozygous mild missense mutation was identified in one
patient with a mild maculopathy. In families G to K, we
identified two novel truncating nonsense mutations (families G
and H), a deletion causing a splice defect (family G), and a
missense mutation that is unanimously predicted to be
pathogenic (family K). The function of IMPG2 is vital for
retinal survival and function, as most IMPG2 mutations that are
identified in our patients can be considered true loss-of-
function alleles. Until now, only one homozygous mild
(missense) mutation in IMPG2 has been described in a single
patient with an isolated maculopathy and a mildly affected
visual function.13 This might indicate that a minimal loss of
function of the IMPG2 protein may result in mild or even
absent retinal disease.
Each of the seven nonsense mutations lead to either mRNA
breakdown because of nonsense-mediated decay, or predicted
truncated IMPG2 proteins that all lack the transmembrane
domain and the cytoplasmic tail. The in-frame deletion
identified in family A (c.888-1554_908þ274del; absence of
seven amino acids) is thought to result in a nonfunctional
IMPG2 protein, as in a cellular transfection assay this mutant
protein was retained in the endoplasmic reticulum, whereas
IMPG2 is physiologically located in the cell membrane.13 The
4–base-pair deletion of the splice acceptor site in family G
(c.3423-8_c.3423-5del) was found to result in the use of an
alternative splice acceptor site, and thereby also predicted to
result in the generation of a truncated protein that most likely
has reduced or no remaining function. Interestingly, the
p.Arg906* was present in 8 of 20 alleles (40%) in 10 Dutch
patients, which may imply a founder mutation in the Dutch
population.
Because the identified mutations cause (near-)complete loss
of IMPG2 function, the clinical variation is limited in IMPG2-
associated RP. The patients in family G, however, retained
slightly better visual acuity and visual field compared with the
other patients (Fig. 2; Table 1). This could imply that the splice
defect in this family results in an IMPG2 protein with some
residual function. However, functional assays are needed to
reveal the true effect of the c.3423-8_c.3423-5 deletion, as
there also is evidence of modifying factors in this family (Table
1; Figs. 2, 3B, 3H, 4) that influence the intrafamilial differences.
The IMPG2 protein (SPACRCAN) is highly homologous to
SPACR, the product of the interphotoreceptor matrix proteo-
glycan 1 (IMPG1) gene, which has been linked to benign
concentric annular macular dystrophy (BCAMD) and vitelli-
form macular dystrophy (VMD).38,39 Interestingly, BCAMD
includes parafoveal hypopigmentation and RP-like fundoscopic
changes in the end-stage disease, although visual acuity is
generally better preserved than in the IMPG2-associated RP
patients in this report.38 The IMPG1-associated vitelliform
dystrophy is also associated with macular pathology, although
this is characterized by accumulation of lipofuscin rather than
a BEM.39
In conclusion, severe mutations in IMPG2 are the cause of
an autosomal recessive RP phenotype that manifests in the
early teens and is accompanied by atrophic maculopathy often
in a bull’s eye pattern. In early disease stages, the maculopathy
is characterized by mild RPE alterations, but in later stages of
the disease, a BEM and profound macular chorioretinal atrophy
may occur. In most patients, the RP phenotype arising from
mutations in the IMPG2 gene is severe, because of the
unfortunate combination of progressive constriction of the
visual fields and maculopathy that occurs relatively early in the
course of the disease.
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